Humacyte, Inc. (HUMA), a biotechnology company specializing in bioengineered human tissues, on Friday, announced that the FDA has granted full approval for SYMVESS (acellular tissue-engineered vessel) for use as a vascular conduit in extremity arterial injury.
This approval follows the program's Regenerative Medicine Advanced Therapy (RMAT) designation in May 2023 and a Priority Review granted in February 2024. The BLA was submitted in December 2023.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.